Status:

COMPLETED

Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

Lead Sponsor:

George Sakoulas, MD

Collaborating Sponsors:

Octapharma

Conditions:

Sars-CoV2

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019...

Detailed Description

This is an investigator initiated, open label, multicenter, two arm, randomized study to compare the impact of adding IVIG to the Standard of Care (SOC) to the SOC without IVIG. Randomization will be ...

Eligibility Criteria

Inclusion

  • Confirmed COVID-19 positive test result (including presumptive positive).
  • Hospitalization
  • Requiring ≥4 liters/min O2 nasal cannula to maintain oxygen saturation ≥ 92%, but not mechanically ventilated
  • Age ≥18 years old.
  • Access to a phone in the hospital room or an electronic device that is capable of receiving phone calls and/or video calls and/or e-mail.
  • Able to read/write/speak English or Spanish fluently.
  • Subjects must have the capacity to provide consent or an appropriate Legally Authorized Representative (LAR) to provide informed consent.
  • provide informed consent, and provide authorization of use and disclosure of personal health information.
  • Negative pregnancy test for women of childbearing potential.

Exclusion

  • Severe allergy to any IVIG product formulation
  • History of DVT, PE, thromboembolic stroke or other thrombotic events
  • Hypersensitivity to corn. Octagam® contains maltose which is a sugar derived from corn.
  • Uncontrolled hypertension (SBP\>180 mm Hg or DBP\>120mmHg)
  • Active participant in another research treatment study
  • Mechanically ventilated patient
  • Code status is Do Not Resuscitate or Do Not Intubate

Key Trial Info

Start Date :

April 28 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 23 2020

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT04411667

Start Date

April 28 2020

End Date

June 23 2020

Last Update

June 25 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sharp Grossmont Hospital

La Mesa, California, United States, 91942

2

Sharp Memorial Hospital

San Diego, California, United States, 92123